Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2003

View Archived Issues

Valentis and Schering sign multiproduct agreement for gene-based therapeutic products

Campath enters phase I/II trial in NHL

Milnacipran demonstrates analgesic efficacy in animal model of FMS

G17DT granted orphan drug status in Australia for gastric and pancreatic cancers

Cephalon files sNDA for Provigil

Olux approved for treatment of psoriasis

Bicifadine enters phase III for postsurgical dental pain

Oxigene begins phase II trial of CA4P in thyroid cancer

CeNeS outlicenses CEE-03-310 to Swiss biopharmaceutical company

Joint development agreement signed by Beaufour Ipsen and Roche for new anticancer drugs

Collaboration to develop drugs for atrial fibrillation renewed by ICAgen and BMS

Novartis files supplemental NDA for Starlix

Genelabs submits MAA for lupus drug in Europe

Relpax granted FDA approval

SuperGen submits first module of rolling NDA for Orathecin

Genentech and Xoma submit BLA for FDA approval of Raptiva

Foradil Certihaler filed for approval in the U.S.

Beneficial long-term effects of arzoxifene on bone and lipids in ovariectomized rats

Inhibition of tight junction function as a novel approach to breast cancer

Highly potent, orally available human glucagon receptor antagonist with antihyperglycemic activity

Potential antileukemia agents selected from series of arsonic acids

Meiji Seika identifies potent, selective and orally available 5-HT7 receptor antagonist

Small-molecule GFRalpha-1 agonist mimics effects of GDNF in neuroblastoma cells

New modulators of glucose and lipid levels designed by Dr. Reddy's researchers

Humira approved by FDA for RA

Azido-based photosensitizers covered by Mallinckrodt patent

Adenine nucleotide translocator-binding compounds and their use reported by MitoKor

Novel prodrugs of FBPase inhibitors prepared and tested at Metabasis Therapeutics

Tularik presents new CXCR3 antagonists with utility in restenosis and other disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...